Skip to main content

Advertisement

Table 2 GPELF MDA treatments (2000–2014)

From: The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000–2014)

WHO region GPELF countries (2000–2014)a Pre-control number at-risk of infection (millions)b Minimum number treated 2000–2014 (millions)c
AMRO Brazil, Dominican Republic, Guyana, Haiti. 14 10
AFRO Benin, Burkina Faso, Cameroon, Central African Republic, Comoros, Congo, Côte d’Ivoire, Democratic Republic of Congo, Ethiopia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Madagascar, Malawi, Mali, Mozambique, Niger, Nigeria, Senegal, Sierra Leone, Tanzania (incl. Zanzibar), Togo, Uganda. 425 191
EMRO Egypt, Sudan Yemen. 23 3
WPRO American Samoa, Brunei Darussalam, Cambodia, Cook Islands, Fed. States of Micronesia, Fiji, French Polynesia, Kiribati, Lao PDR, Marshall Islands, Malaysia, Niue, Papua New Guinea, Philippines, Samoa, Tonga, Tuvalu, Vanuatu, Vietnam, Wallis and Futuna. 45 24
SEARO Bangladesh, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand, Timor-Leste. 902 536
All Regions 61 countries in total d 1409 763
  1. AMRO Region of the Americas, AFRO African Region, EMRO Eastern Mediterranean Region, WPRO Western Pacific Region, SEARO South-East Asia Region
  2. aCountries that started since 2007 are indicated in bold
  3. bData taken from [5, 6]
  4. cA conservative approach was taken and the number of uniquely treated individuals in any one country was assumed to be the maximum number of individuals treated in any single MDA for each country
  5. d Palau has passed the TAS survey but never started MDA so is not included